Search Results
Jun 01, 2024, 20:00 ET Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
received curative resection.Professor Yu Chen, Fujian Cancer Hospital, stated: "Melanoma is a rare tumor type in China, and the majority of patients are acral or mucosal subtypes, which are not sensitive to immunotherapy
More news about: Innovent Biologics
Jun 01, 2024, 08:00 ET TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced interim results from the Phase 1b clinical trial of TU2218 in combination with pembrolizumab
More news about: TiumBio
May 31, 2024, 14:26 ET FDA Roundup: May 31, 2024
Support for Clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. The pilot,
More news about: U.S. Food and Drug Administration
May 31, 2024, 12:59 ET SIFI reçoit un avis positif du CHMP pour AKANTIOR® (polihexanide 0,08 %) pour la kératite à acanthamoeba
d'AKANTIOR® (polihexanide sous le nom international non propriétaire), pour le traitement de la kératite à acanthamoeba, une maladie ophtalmique rare. « Nous sommes très heureux d'avoir reçu cet avis positif de la part du CHMP pour AKANTIOR®. Si elle est approuvée, cette solution
More news about: SIFI S.p.A.
May 31, 2024, 09:00 ET Myasthenia Gravis Foundation of America (MGFA) Announces Global Kickoff of Myasthenia Gravis Awareness Month
Kicks Off MG Awareness Month for June.The global MG Community is turning Awareness into Action to educate everyone about the challenges of the rare neuromuscular disease myasthenia gravis (MG). Individuals diagnosed with myasthenia gravis as well as caregivers, medical experts and researchers, pharmaceutical
More news about: Myasthenia Gravis Foundation of America, Inc.
May 31, 2024, 09:00 ET AN IDYLLIC ISLAND OASIS: TA'AKTANA, A LUXURY COLLECTION RESORT & SPA, LABUAN BAJO DEBUTS ON THE PEARLESCENT SHORES OF INDONESIA
TA'AKTANA, a Luxury Collection Resort & Spa, Labuan Bajo is a natural and stunning fit. The Luxury Collection provides today's global travelers with rare experiences that are deeply reflective of the destination, and through that lens we invite guests to discover the beauty and vibrant history of Labuan
More news about: Marriott International, Inc.
May 31, 2024, 08:30 ET Leading the New Energy Vehicle Industry
in future. Currently, Canada does not have a domestically developed new energy vehicle brand. To seize this rare opportunity, Visionary is actively developing in the new energy field, striving to become the first Canadian company to develop and supply its own brand
More news about: Visionary Holdings Inc.
May 31, 2024, 08:21 ET Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
conditions including anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré syndrome (GBS) and as a pre-treatment to gene therapy in rare disease patients with pre-existing antibodies. This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market
More news about: Hansa Biopharma AB
May 31, 2024, 08:12 ET Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
conditions including anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré syndrome (GBS) and as a pre-treatment to gene therapy in rare disease patients with pre-existing antibodies. This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market
More news about: Hansa Biopharma AB
May 31, 2024, 08:00 ET As the second European Myasthenia Gravis Awareness Day unfolds, 'All United for MG' amplifies the call for action
More than 1,600 people have signed a petition calling for greater awareness about Myasthenia Gravis (MG), a rare and often debilitating disease, and would like to see collective action that will enhance management of this chronic condition The petition that was launched by the European patient
More news about: All United for MG
May 31, 2024, 08:00 ET Defense Metals Appoints Suzanne Rich Folsom to the Board of Directors
("PFS") to be prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Minerals Projects, for its 100% owned Wicheeda Rare Earth Element ("REE") project located near Prince George, B.C., Canada. All infrastructure geotechnical
More news about: Defense Metals Corp.
May 31, 2024, 07:30 ET Soligenix Announces Reverse Stock Split
Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split
More news about: SOLIGENIX, INC.
May 31, 2024, 07:00 ET Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including
More news about: Ionis Pharmaceuticals, Inc.
May 31, 2024, 04:20 ET Following the FDA, EMA also Grants an Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer.
May 24 that European Medicines Agency(EMA) had granted an orphan drug designation for small cell lung cancer(SCLC), a rare disease, for SNB-101 (API: SN-38) which is a new polymer nanoparticle drug under development.
More news about: SN BioScience Inc
May 31, 2024, 03:00 ET SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
recommending approval of AKANTIOR® (polihexanide under the international non-proprietary name), for the treatment of acanthamoeba keratitis, a rare ophthalmic disease. "We are very pleased to have received this positive opinion from the CHMP for AKANTIOR®. If approved, this innovative
More news about: SIFI S.p.A.
May 31, 2024, 03:00 ET SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
recommending approval of AKANTIOR® (polihexanide under the international non-proprietary name), for the treatment of acanthamoeba keratitis, a rare ophthalmic disease. "We are very pleased to have received this positive opinion from the CHMP for AKANTIOR®. If approved, this innovative
More news about: SIFI S.p.A.
May 30, 2024, 22:30 ET U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
commonly diagnosed cancer worldwide.7 In the U.S., it is estimated that 130,263 people are living with gastric cancer, classifying it as a rare disease.1,8 In 2024, it is estimated that 26,890 people will be diagnosed with gastric cancer and 10,880 will die from the disease in the
More news about: ASTELLAS PHARMA INC.
May 30, 2024, 19:28 ET Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Telix's lead imaging product, gallium-68 (68Ga) gozetotide
More news about: Telix Pharmaceuticals Limited
May 30, 2024, 18:01 ET Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
Europe: Results from the PRISM Survey (Abstract P2292)About Systemic Mastocytosis Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe
More news about: Blueprint Medicines Corporation
May 30, 2024, 16:07 ET Tune.FM and Space Blue Announce Partnership for Exclusive Rights to Rare Compilation from Jimi Hendrix, Bob Marley, Carlos Santana, The Who, Marvin Gaye, Eric Clapton and The Yardbirds, Other Iconic Artists
community that combines artists, NFTs and projects that are driven by a shared passion for space and a sustainable future, announced plans today to unveil a rare compilation including live performances by some of the world's most iconic musicians including Jimi Hendrix, Bob
More news about: Tune.FM
May 30, 2024, 16:05 ET Insmed to Host Commercial Webinar on June 4, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss
More news about: Insmed Incorporated
May 30, 2024, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential
More news about: Viking Therapeutics, Inc.
May 30, 2024, 14:55 ET Contract Research Organization (CRO) Market size is set to grow by USD 63.35 billion from 2024-2028, Growth of biopharmaceutical industry boost the market, Technavio
the CRO market include the use of technology to streamline processes, the growth of emerging markets, and the focus on specialized services such as rare disease research. The CRO market also faces challenges such as regulatory compliance, data security, and the need for high-quality data. Overall, the
More news about: Technavio
May 30, 2024, 14:20 ET Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that EMA now has issued
More news about: Calliditas Therapeutics
May 30, 2024, 14:18 ET Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that EMA now has issued
More news about: Calliditas Therapeutics